Kritische 8-K Meldungen
Stammdaten
Unternehmen
| Name | Allogene Therapeutics, Inc. |
|---|---|
| Ticker | ALLO |
| CIK | 0001737287 |
Branche
| SIC-Code | 2836 |
|---|---|
| Beschreibung | Biological Products, (No Diagnostic Substances) |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | Allogene Therapeutics, Inc. |
Status
| Zuletzt geprüft | 2026-03-23 02:58:40.496816 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -4,835 | 2.47 | -11,942.45 | -25,4% | |
| 2026-03-16 | Chang David D | Director, Officer, President and CEO | Open Market Sale | -47,763 | 2.47 | -117,974.61 | -250,7% | |
| 2026-03-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,132 | 2.60 | -18,543.20 | -39,4% | |
| 2026-03-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,132 | 2.60 | -18,543.20 | -39,4% | |
| 2026-02-02 | Chang David D | Director, Officer, President and CEO | Open Market Sale | -95,269 | 1.80 | -171,484.20 | -364,5% | |
| 2026-02-02 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -24,001 | 1.76 | -42,241.76 | -89,8% | |
| 2026-02-02 | Yoshiyama Annie | Officer, SVP, Finance | Open Market Sale | -4,167 | 1.72 | -7,167.24 | -15,2% | |
| 2026-02-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,549 | 1.73 | -13,059.77 | -27,8% | |
| 2026-02-02 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -7,549 | 1.73 | -13,059.77 | -27,8% | |
| 2026-02-02 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -24,001 | 1.76 | -42,241.76 | -89,8% | |
| 2026-02-02 | Chang David D | Director, Officer, President and CEO | Open Market Sale | -95,269 | 1.80 | -171,484.20 | -364,5% | |
| 2026-02-02 | Douglas Earl Martin | Officer, SVP, General Counsel | Open Market Sale | -22,900 | 1.76 | -40,304.00 | -85,7% | |
| 2026-02-02 | Douglas Earl Martin | Officer, SVP, General Counsel | Open Market Sale | -22,900 | 1.76 | -40,304.00 | -85,7% | |
| 2026-02-02 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -35,700 | 1.77 | -63,189.00 | -134,3% | |
| 2026-02-02 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -35,700 | 1.77 | -63,189.00 | -134,3% | |
| 2026-01-21 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -26,269 | 1.56 | -40,979.64 | -87,1% | |
| 2026-01-21 | Roberts Zachary | Officer, EVP of R&D | Open Market Sale | -26,269 | 1.56 | -40,979.64 | -87,1% | |
| 2025-11-17 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -786 | 1.22 | -958.92 | -2,0% | |
| 2025-11-17 | Beneski Benjamin Machinas | Officer, SVP, Chief Technical Officer | Open Market Sale | -786 | 1.22 | -958.92 | -2,0% | |
| 2025-10-21 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -36,744 | 1.26 | -46,168.84 | -98,1% | |
| 2025-10-21 | Parker Geoffrey M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -36,744 | 1.26 | -46,168.84 | -98,1% | |
| 2025-06-10 | MESSEMER DEBORAH M. | Director | Open Market Sale | -36,885 | 1.42 | -52,376.70 | -111,3% | |
| 2025-06-10 | MESSEMER DEBORAH M. | Director | Open Market Sale | -36,885 | 1.42 | -52,376.70 | -111,3% | |
| 2025-04-21 | Yoshiyama Annie | Officer, SVP, Finance | Open Market Sale | -9,601 | 1.41 | -13,537.41 | -28,8% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.